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ABSTRACT 
Population genetic simulation study of power in association testing across genetic 
architectures and study designs 
 
Dominic Tong 
 
The role of rare variants in complex disease is hotly debated, but the design of genetic association 
studies to statistically associate rare variants is not well understood. Here, we simulate rare variant 
association studies across different case/control panel sampling strategies, sequencing methods, 
and genetic architecture models based on evolutionary forces to determine the statistical 
performance of RVATs widely in use. We find that the highest statistical power of RVATs is 
achieved by sampling case/control individuals from the extremes of an underlying quantitative 
trait distribution. We also demonstrate that the use of genotyping arrays, in conjunction with 
imputation from a whole genome sequenced (WGS) reference panel, recovers the vast majority 
(90%) of the power that could be achieved by sequencing the case/control panel using current 
tools. Finally, we show that the statistical performance of RVATs decreases as rare variants 
become more important in the trait architecture. Our work shows that RVATs are not yet well-
powered enough to make generalizable conclusions about the role of rare variants in complex trait 
architectures. 
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Chapter 1: Introduction 
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The advent of massively-parallel high-throughput ‘-omics’ technologies, combined with 
the Moore’s Law increase in computational power, has enabled a revolution in the way 
discoveries in biology are made. In the past, Gregor Mendel bred peas in his monastery’s 
experimental garden to observe and formulate the laws of Mendelian inheritance; Charles 
Darwin collected and observed finches in the Galapagos Islands before eventually coming to the 
theory of evolution in London; Fisher, Wright, and Haldane all gathered observations by hand to 
make their immense contributions to the field of population and statistical genetics. In 2019, we 
are able to sequence hundreds of thousands of whole human genomes, able to make edits to 
genomes in vitro and observe their effects, and empirically demonstrate the theories from the 
grand trio of Fisher, Wright, and Haldane, while adding wrinkles of our own. It astounds me that 
I present statistical genetics research, while, as Newton said, standing on the shoulders of giants. 
In this thesis, I focus on understanding the link between genetics and phenotype by 
thoroughly characterizing our existing statistical association methods within a simulation 
framework. It is clear that the use of genome sequencing and “big data” approaches has the 
potential to revolutionize our understanding of the genetic architecture underlying phenotypes 
and vastly improve the discovery of drugs and treatment of individuals within the healthcare 
system, termed “precision medicine”. This potential has yielded some fruit, in screening for 
breast cancer (Mavaddat et al., 2010), in warfarin dosing (Dean, 2012), in identifying a 
significant risk factor for cardiovascular disease (Cohen et al., 2006), but the statistical tests 
underlying these detected common variant associations are under-powered to detect rarer causal 
variants. To measure the impact of the genetic variants associated, we use the total heritability of 
the trait, a statistic used in the fields of breeding and genetics that estimates the degree of 
variation in a phenotypic trait in a population that is due to genetic variation between individuals 
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in that population. In many cases, this heritability is much greater than the heritability explained 
by the associated genetic variants using current statistical tests.  
One proposed source of this so-called “missing heritability” are rare variants, which are 
hotly debated but have been implicated as a non-negligible source of genetic variance in prostate 
cancer (Mancuso et al., 2016), gene expression (Hernandez et al., 2017), height and BMI 
(Wainschtein et al., 2019). Unfortunately, power to detect rare variant associations is low in single-
marker statistical tests at the genome-wide scale. Researchers have proposed many rare variant 
association tests (RVATs), statistical methods to pool rare variants within a putatively causal locus 
and test for association with the phenotype. These RVATs are broadly classified into three 
categories: burden tests (Liu & Leal, 2010), variance-component tests (Neale et al., 2011; Wu et 
al., 2011), and combined tests (Lee et al., 2012; Sun, Zheng, & Hsu, 2013). Though each test is 
published with its own validation simulations, these simulations are generally not comparable, and 
have their own flaws. (Moutsianas et al., 2015) systematically characterized the performance of 
commonly used gene-based rare variant association tests under a range of genetic architectures, 
sample sizes, variant effect sizes, and significance thresholds, and found that MiST, SKAT-O, and 
KBAC have the highest mean power across simulated data, but that these tests had overall low 
power even in the cases of loci with relatively large effect sizes. 
It is well-known in the population genetics literature that population expansions and 
contractions (i.e. demography) can dramatically affect genome-wide patterns of genetic variation 
in a population (Auton et al., 2009; Bhaskar, Wang, & Song, 2015; Gravel et al., 2011; Uricchio, 
Zaitlen, Ye, Witte, & Hernandez, 2016), and that the action of natural selection can amplify or 
inhibit the frequency of functional alleles (Boyko et al., 2008; Adam Eyre-Walker, Woolfit, & 
Phelps, 2006; Lohmueller et al., 2011). Together, these evolutionary forces shape the genetic 
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architecture of complex traits (Lohmueller, 2014; Uricchio et al., 2016), and are critical 
components to understand in the pursuit of identifying the genetic basis for the bevy of human 
phenotypes understudy. Inferred demographic models of non-African human populations show a 
serial bottleneck model as populations migrated in waves across the globe, followed by explosive 
exponential growth since the dawn of agriculture. Moreover, studies of selection have found that 
most amino acid changes in proteins and changes in conserved non-coding loci are weakly 
deleterious (Boyko et al., 2008; Torgerson et al., 2009). Together, growth and selection has 
resulted in a preponderance of ultra-rare mutations (MAF<0.1%), which contribute a plurality of 
heritability in gene expression (Hernandez et al., 2017), BMI (Wainschtein et al., 2019), and 
possibly other traits. Accounting for demographic and selective effects on the frequency spectrum 
of causal variation is therefore crucial in characterizing the statistical power of RVATs. However, 
while previous evaluations of RVAT power have attempted to mimic the frequency spectrum of 
observed variants, they typically use phenotype models (or genetic architectures) that do not 
directly account for evolutionary forces like demography and natural selection and are often 
biologically unrealistic [e.g. effect sizes that are simple functions of the minor allele frequency 
(Wu et al., 2011)], limited to specific relative risks (Wray & Goddard, 2010), or lack pleiotropy 
(Moutsianas et al., 2015). 
Another vital component of designing genetic association studies is the method of 
acquiring genetic data. Although the gold standard for capturing rare variation remains deep whole 
genome sequencing (WGS), the $1000 per genome cost still means performing WGS on any 
sizeable group of individuals remains prohibitively expensive for all but the largest consortia. 
Genotyping arrays make acquiring genetic data for a large number of individuals significantly less 
expensive, but lack coverage of rare variation. With larger WGS reference panels like the 
5 
 
Haplotype Reference Consortium (HRC; McCarthy et al., 2016), large numbers of genotyped 
samples can be imputed to gain some insight into rare variation. With such large reference panels, 
imputation coverage of genetic variation down to MAF≅0.1% is near perfect in European 
individuals (Quick et al., 2019). As more diverse reference panels become available [e.g. TOPMed 
(Taliun et al., 2019)], imputation in non-European and admixed populations will also improve, 
particularly for rare variants. Capturing these rare variants using genotyping arrays and imputation 
is more cost-effective and can lead to many more individuals in a study. However, imputation is 
limited by the variants that are carried by the individuals in the reference panel, and by the accuracy 
of the algorithm being used. Imputation accuracy falls off at lower minor allele frequencies (MAF), 
but the use of large WGS reference panels reduces the threshold of acceptable imputation quality 
(r2>0.3) to ~0.004-0.006% (Taliun et al., 2019) in European and African populations. Despite these 
limitations, imputation has been used to identify rare variant associations in acute macular 
degeneration (Helgason et al., 2013), lipid levels in type 2 diabetes patients (Marvel et al., 2017), 
systemic lupus erythematosus (Martínez-Bueno & Alarcón-Riquelme, 2019), among others. It is 
possible that additional rare variant association signals can be found in imputed data as imputation 
quality improves, but it is unclear what the statistical properties of RVATs in this setting are.  
In this thesis, I evaluate the statistical power of rare variant association tests in a simulation 
study under different genetic architectures, methods of acquiring genetic data, and methods of 
selecting individuals to be a part of the case-control cohort. I demonstrate how statistical power of 
RVATs is dependent on genetic architecture as well as sampling strategy for the case/control 
cohort. In particular, I find that sampling the extremes of a quantitative phenotype has the highest 
RVAT power, but counterintuitively, power erodes quickly for all sampling strategies as the 
amount of genetic variance explained by rare variants increases.   
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Chapter 2: Designing a simulation pipeline to evaluate the statistical power of genetic 
association tests under different genetic architectures and study designs 
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Overview 
To study the statistical power of genetic association tests under a variety of genetic 
architectures and study designs, we constructed a simulation pipeline from existing software and 
wrote code to fill in necessary gaps. This process mimics the process of running an empirical 
genetic association study: to gather genetic and phenotypic data, to impute, and to run association 
tests. The advantage of a simulation is that we have access to the ground truth and can objectively 
evaluate these statistical association tests across a variety of parameters. A brief overview of this 
process is shown in Figure 2.1, and the details follow below. 
  
Figure 2.1 The software pipeline built to study the statistical power of association testing in 
a simulation framework. The branches are for evaluating the power of association test on 
imputation data and on whole genome sequencing (WGS) data. 
Simulating genomic sequence data  
To simulate genomic sequence data, we considered options from each of the classes of 
genetic simulators: haplotype resamplers, forward simulators, and backward or coalescent 
simulators. HAPGEN2 (Su, Marchini, & Donnelly, 2011), a haplotype resampler, was initially 
selected to match the method in (Moutsianas et al., 2015); however, our lab has previously shown 
that HAPGEN2 would simulate too few rare variants (Uricchio, Torres, Witte, & Hernandez, 2015) 
and efforts to scale up the mutation rate ran into memory and coding issues. I moved on to using 
SFS_CODE (R. D. Hernandez, 2008), a forward simulator that efficiently mimics the course of 
evolution given a human demographic model and evolutionary parameters like recombination rate, 
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and mutation rate. However, these simulations were not feasible on the scales required to 
investigate modern genetic association tests. Thankfully, Kelleher and colleagues developed an  
efficient coalescent simulator in 2016 (Kelleher, Etheridge, & McVean, 2016), where they 
simplified the storage and traversal of trees key to doing these simulations a hundredfold. This 
advance enabled me to simulate the genetic sequences required under a realistic demographic 
model and realistic evolutionary parameters to comprehensively evaluate modern statistical 
association tests. 
We simulate neutral genetic sequence data under a coalescent model using msprime 
(Kelleher et al., 2016) with a European and African demographic history (Tennessen et al., 2012). 
Under this demographic model, the European population experienced a series of bottlenecks as 
they moved out of Africa and into Europe. These bottlenecks were followed by super exponential 
growth in the European population and recent exponential growth in the African population, along 
with bi-directional migration. Using this neutral demographic model, we generate a 5Mb region 
with a mutation rate of 1e-8 and with genetic map arbitrarily chosen to mimic chr22:17000000-
22000000 in hg19.  
Simulating genotype data  
Some analyses are based on genotype array data. To simulate a genotyping array, we 
downsample the simulated neutral sequence data above to match the allele frequency spectrum 
and the average distance between variants of the Illumina OmniExpress2.5 genotyping chip, used 
in the GoT2D study (Fuchsberger et al., 2016). Though other genotyping arrays exist, we take this 
Illumina chip to be the standard, and this choice is unlikely to matter in simulated genetic data 
regardless. We do not simulate errors in the genotyping process here, so results from this 
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simulation will overestimate the overall effectiveness of genotyping then imputing as a method of 
collecting genetic data. 
Simulating quantitative phenotypes 
To simulate phenotypes needed for a genetic association study, we need a phenotype 
model. We considered several models and software packages to do so. Some models were overly 
simplistic, like the Wu et al, 2011 model which simply assumes a logarithmic relationship between 
effect size and minor allele frequency (𝑧𝑧 = log(𝑥𝑥), where z is the effect size and x is the minor 
allele frequency). Other models relied on relative risks of a certain genetic variant [Wray and 
Goddard 2010], for which there is no real theoretical basis, and is hard to arbitrarily assign. The 
model Moutsianas et al, 2015 used is a step in the right direction, using the selection coefficient 
on a particular genetic variant as a basis for computing the effect size, but this model, based on (A. 
Eyre-Walker, 2010) lacks pleiotropy. We therefore use the Uricchio model, which computes an 
effect size for a genetic variant based on that variant’s selection coefficient, and accounting for 
pleiotropic effects. 
We transform our simulated neutral genetic data into quantitative phenotypes using a three-
step procedure, following Uricchio et al (Uricchio et al., 2016). First, we simulate functional 
variants using the forward simulator SFS_CODE (Hernandez, 2008) under the same demographic 
model as above, but with purifying selection. Specifically, we generate 2000 independent loci of 
length 100kbp (for a total of 200Mb) with 100,000 individuals, where new mutations receive a 
fitness effect drawn from a gamma distribution [as inferred for non-synonymous sites (Boyko et 
al., 2008)]. This procedure generates a large table of functional variants, with corresponding 
derived allele counts and fitness effects.  
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The second step is to project the allele frequencies of our list of functional variants down 
to the desired sample size (using a binomial model), and transform fitness effects to phenotypic 
effect sizes using the Uricchio et al. model (Uricchio et al., 2016). This model parameterized the 
correlation between fitness effects and phenotypic effect sizes (through ⍴) and the functional 
relationship between fitness effects and phenotypic effect sizes (through 𝜏𝜏 and 𝛿𝛿). In particular, a 
causal variant with fitness effect 𝑠𝑠 will have effect size 𝑧𝑧𝑠𝑠 as follows:  
𝑧𝑧𝑠𝑠 = �𝛿𝛿𝑠𝑠𝜏𝜏 with probability 𝜌𝜌𝛿𝛿𝑠𝑠𝑟𝑟𝜏𝜏 otherwise                
 
Under this model, with probability 𝜌𝜌, the effect size 𝑧𝑧𝑠𝑠 of a site is a direct function of the 
site’s fitness effect (𝑠𝑠), otherwise the effect size 𝑧𝑧𝑠𝑠 is a function of a randomly sampled fitness 
effect (𝑠𝑠𝑟𝑟) drawn from the entire list of functional variants generated by the first step above. In this 
model, 𝛿𝛿 is +1 or -1 with equal probability to enable trait-increasing and trait-decreasing effects.  
The third step for generating quantitative phenotypes is to identify the desired number of 
causal loci in our 5mb simulated sequence. For each variant within the causal loci, we sample a 
random variant from our list of functional variants generated in step two with the exact same allele 
frequency, and assign derived alleles at this causal site the effect size of the sampled functional 
variant. The quantitative phenotype of each individual (𝑌𝑌𝑖𝑖, for the ith individual) is then generated 
under an additive model by summing the effect sizes of all causal alleles that they carry: 
 
𝑌𝑌𝑖𝑖 = �𝑋𝑋𝑖𝑖𝑖𝑖𝑧𝑧𝑖𝑖 + 𝜖𝜖
𝑖𝑖
 
 
19 
 
Where 𝑧𝑧𝑖𝑖 is the effect size of causal variant 𝑗𝑗, 𝑋𝑋𝑖𝑖𝑖𝑖 is the number of causal alleles carried by 
individual 𝑖𝑖 at site 𝑗𝑗, and 𝜖𝜖 is a Normal random variable with mean 0 and variance 𝜎𝜎𝑒𝑒𝑒𝑒𝑒𝑒𝑖𝑖𝑟𝑟𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒𝑒2  
(which ensures the desired level of heritability of the trait). See Table 1 for the specific values of 
⍴, 𝜏𝜏, and heritability that are evaluated in this study.  
 
Table 2.1 Genetic architectures examined in this study 
Parameter Values 
Number of causal loci 10, 100 
Heritability (h2) 0.2, 0.8 
⍴ 0.5, 0.8, 0.9, 1.0 
𝜏𝜏 0.5, 1.0 
 
Selecting sampling strategies for association tests 
The quantitative phenotypes can be dichotomized to simulate three different sampling 
strategies: random, 50/50, and extremes. In the extreme sampling strategy, we sample the desired 
number of individuals from the top and bottom of the quantitative phenotype distribution. For the 
random and 50/50 sampling strategy, we first define the individuals with quantitative phenotypes 
in the top P% to be our population of cases (where P represents the prevalence of our trait of 
interest, set at 25%), and the remaining individuals to be our population of controls. We then 
sample cases and controls from their respective populations. For the random sampling strategy, 
we sample cases in proportion to the prevalence of the trait, while for the 50/50 sampling strategy 
we sample equal numbers of cases and controls. The random sampling strategy is used as a worst-
case scenario to establish the worst possible power under that sampling strategy. 
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Table 2.2 Study design parameters in this study 
Parameter Value 
Study design Random, 50/50, Extremes 
Number of case/control individuals 5000, 10000 
Number of reference panel individuals for imputing 10000, 20000 
 
 
Imputing genotyped data 
In some analyses, we evaluate the effectiveness of genotype imputation. Such analyses 
require two data sets: the phenotype sample (e.g. case/control or continuous phenotype), and an 
imputation reference panel. The dichotomized phenotype individuals are generated as above, with 
their genetic data down-sampled to mimic a genotype array platform. We then sample an additional 
set of individuals from the total population to form the imputation panel. The down-sampled 
genotype data is then pre-phased using SHAPEIT2 (Delaneau, Marchini, & Zagury, 2012) and 
imputed using IMPUTE4 (Bycroft et al., 2017). We considered other imputation algorithms, 
particularly BEAGLE (Browning, Zhou, & Browning, 2018) and minimac (Das et al., 2016), but 
these proved problematic with memory and software constraints. IMPUTE4, being a newly 
developed algorithm at the time, far outperformed BEAGLE and minimac, and so was selected for 
this study. 
Running tests of association on simulated data 
We ran rare variant association tests (RVATs) using the rvtests software (Zhan, Hu, Li, 
Abecasis, & Liu, 2016). We focus on SKAT (Wu et al., 2011), SKAT-O (Lee et al., 2012), and 
KBAC (Liu & Leal, 2010), which were found to be most powerful in detecting disease-associated 
variation in a previous study (Moutsianas et al., 2015). We applied each RVAT to non-overlapping 
analysis blocks of 10kbp across the simulated region, and computed power and false-positive rates 
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for each test as the proportion of simulations with p-values below 2.5e-6. We ran logistic 
regression on each variant above MAF=1% to determine associations with the phenotype using 
PLINK. The detection threshold was set at 5e-8. To compare GWAS to RVAT power, we evaluate 
if there is a variant under the GWAS p-value threshold within the 10kb analysis block. If there is 
such a variant, we deem the GWAS to have found that analysis block to be causal for comparisons 
with RVAT.  
Calculating cumulative genetic variance 
We follow (Uricchio et al., 2016) in calculating 𝑉𝑉𝑥𝑥, the genetic variance due to variants at 
or below allele frequency 𝑥𝑥, which is given by: 
𝑉𝑉𝑥𝑥 = 0.5� 𝐸𝐸(𝑧𝑧2|𝑦𝑦) 𝑓𝑓(𝑦𝑦)(1 − 𝑦𝑦)(𝑦𝑦)𝑑𝑑𝑦𝑦𝑥𝑥 
𝑦𝑦=0
  
Where 𝑓𝑓(𝑦𝑦)is the site frequency spectra (SFS), i.e. the proportion of sampled alleles at frequency 
𝑦𝑦, and 𝐸𝐸(𝑧𝑧2|𝑦𝑦) is the mean-squared effect size of variants at frequency 𝑦𝑦. We pool 20 simulations 
of 300kbp in 50k African individuals using msprime to obtain an accurate measure of the SFS and 
the expected effect size of variants at frequency 𝑥𝑥. To normalize across genetic architectures, we 
divide by 𝑉𝑉1, which is the total additive genetic variance. The 𝑉𝑉0.01/𝑉𝑉1 values (denoted as just 
𝑉𝑉′0.01 below) are used to denote the degree to which rare variants (variants with MAF ≤ 1%) matter 
under a particular pair of parameters under the Uricchio genetic architectures. 
Table 2.3 Genetic architecture parameters under the Uricchio model and the genetic variance 
explained by variants under MAF=1%. 
𝜏𝜏 ⍴ V′0.01 
0.5 0.5 0.23191008598492735 
 
0.8 0.35820017698651052 
 
0.9 0.40029687398703817 
 
1.0 0.44239357098756588 
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𝜏𝜏 ⍴ V′0.01 
1.0 0.5 0.50718348211637121 
 
0.8 0.79549982205815639 
 
0.9 0.89160526870541801 
 
1.0 0.98771071535267974 
 
Performing Haseman-Elston regression to estimate heritability 
We run Haseman-Elston regression to estimate heritability on our simulated traits. 
Haseman-Elston regression is a linear regression of the normalized covariance of the phenotype 
against the normalized covariance of the genotype (in the form of a genetic relatedness matrix 
(GRM)); the narrow-sense heritability of that phenotype is the slope of the regression line. We 
simulate the phenotype using the Uricchio model, above. We use PLINK v1.90beta (Chang et 
al., 2015) to calculate GRMs for different frequency bins in our samples with the frequency bin 
thresholds as follows: [1.e-05, 2.e-05, 5.e-05, 1.e-04, 2.e-04, 5.e-04, 0.001, 0.01, 0.02, 0.1, 1]. 
We then use GCTA v1.92.0 (Yang, Lee, Goddard, & Visscher, 2011) to run the Haseman-Elston 
regression.  
 
PLINK: /netapp/home/dmctong/programs/plink/plink --vcf ${VCF} --memory ${N_MEM} --
double-id --make-grm-bin --out ${OUT_PREFIX} --mac ${MIN_MAC} --max-mac 
${MAX_MAC} 
GCTA: /netapp/home/dmctong/programs/gcta_1.92.0beta3/gcta64 --HEreg --mgrm 
${GCTA_MULTIGRM} --pheno ${GCTA_PHENO} --out ${PREF_OUT} 
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Rare variants explain a majority of heritability only under restrictive scenarios 
To determine whether there is genetic variance explained by rare variants, we calculated 
the expected genetic variance analytically under different (⍴,τ) combinations of the Uricchio 
model being studied here (see Methods and Table 1). In Figure 1, we show that the proportion of 
genetic variance explained as a function of MAF. We focus on the genetic variance explained by 
variants with MAF < 1% (𝑉𝑉’0.01), which varies dramatically between 99% when ⍴=1, τ=1, to less 
than 1% when ⍴=0, τ=0.5. We note that when τ=1 and ⍴≠0, rare variants constitute a substantial 
fraction of the genetic variance (𝑉𝑉0.01 >  40%), and the majority of the rare variant contribution 
is explained by singletons in this simulated sample of 50,000 individuals. In contrast, when τ=0.5 
and ⍴≠0, V0.01 ranges from ~20%-60% but singletons are expected to make a more subtle 
contribution to the genetic architecture of the trait.  
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Figure 3.1 The cumulative proportion of the genetic variance explained by variants under 
minor allele frequency x (Vx/V1) for a sample of 5000 individuals drawn from an African 
population demographic model under different values of ⍴ and τ in the Uricchio model. Left: 𝝉𝝉 = 
0.5; right: 𝝉𝝉 = 1. Dotted lines indicate the proportion of genetic variance explained by alleles under 
1% MAF (referred to as 𝑽𝑽𝟎𝟎.𝟎𝟎𝟎𝟎).   
Haseman-Elston regression to identify observable heritability in simulation 
Since the range of the phenotype model parameters (Table 2.1) are expected to produce a 
broad range of genetic architectures, we used heritability analyses (based on Haseman-Elston 
regression) to see if there was sufficient evidence in the data to differentiate the various models. 
In Figure 3.2, we show that in a simulated case/control panel of 10000 individuals across a 5Mb 
region, there is a difference in heritability explained by rare variants under the different genetic 
architectures, particularly when in the high heritability condition (h2 = 0.8), and when the 
phenotypic effect sizes are directly correlated to the selection coefficient of that allele (ρ= 1). 
There is also an increase in heritability in the bin where MAF is between 0.5% and 5%, 
indicating there is heritability in causal variants expected to be captured by RVATs.  
Possible reasons that these simulated plots do not match the analytical expectation shown 
in Figure 3.1 are: we do not simulate a sufficiently large genetic region, and hence do not 
generate sufficient numbers of ultra-rare variants to produce substantial rare variant heritability; 
or that stochasticity in the Haseman-Elston estimator is dominating the signal with 300 
simulations; or another yet uncharacterized effect. However, even with only a 10,000 individual 
sample size, there can be a significant amount of heritability explained by rare variants under 
certain genetic architectures, and we can capture a lot of it using heritability estimation methods. 
The next step is to identify the causal loci driving the pattern, but this cannot not be done with 
such heritability analyses. 
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Figure 3.2 Haseman-Elston regression on simulated case/control data shows the inferred 
cumulative heritability explained by variants under a given MAF. True heritabilities in the 
columns (0.2 and 0.8); tau in the rows (0.5 and 1). 300 replicates of a 5Mb region with 10,000 
samples simulated (5,000 cases and 5,000 controls), with 100 causal regions of size 10kb each. 
 
Statistical power varies dramatically across different study designs, genetic architectures, 
and polygenicity, but not across RVATs 
Figure 3.3 shows that rare variants can contribute substantial heritability to a trait under 
certain genetic architectures. Now we ask if we can detect the loci that harbor the causal rare 
variants using existing RVATs. To quantify the effects of genetic architecture and study design on 
the statistical power of RVATs, we focus on KBAC, SKAT, and SKAT-O, which represent each 
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of the three major categories of RVATs and have been shown to be among the most powerful 
(Moutsianas et al., 2015). For the 5Mb region we simulated (see Methods), we raster over 
parameters in genetic architecture (heritability, number of causal loci, and the relationship between 
selection and phenotypic effect sizes; Table 1) and in study design (sequencing vs genotype 
imputation and selection of individuals in the case/control vs extreme phenotype panels). In Figure 
3.2, we show the global overview of statistical power across all simulations in African populations; 
in Figure 3.3, we show the overview for European populations. In African populations, we find 
that the statistical power of all three RVATs is similar regardless of simulated parameters, but tend 
to be highest with SKAT and SKAT-O [pMWU(SKAT, SKAT-O)=0.795; pMWU(KBAC, SKAT-
O)=0.002304]. As expected, power is higher when the causal signal is more concentrated (e.g. 
when heritability is high or the effect sizes are large due to few causal loci). However, in European 
populations, the power of KBAC is much lower across all parameters than in SKAT or SKAT-O 
[pMWU(SKAT, SKAT-O)=0.730; pMWU(KBAC, SKAT-O)=1.883e-6], suggesting that burden tests 
are less effective given the explosive growth in European populations in the Tennessen 
demographic model. In the main figures of this thesis, we will focus on SKAT-O and give the 
results of SKAT and KBAC in the appendices. 
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Figure 3.3 A global overview of the statistical power in 50,000 African individuals of a burden 
test (KBAC), a variance-component test (SKAT), and a combined test (SKAT-O) for all 
parameters shown in Table 2.1 simulated under an Out-of-Africa demographic model. Each point 
represents a genetic architecture tested with 10 independent simulations under the RVAT 
indicated; lines connect the same simulated parameters across RVATs to show that, generally 
speaking, the rank of statistical power is preserved across RVATs.  
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Figure 3.4 A global overview of the statistical power in 50,000 European individuals of a 
burden test (KBAC), a variance-component test (SKAT), and a combined test (SKAT-O) for 
all parameters shown in Table 2.1 simulated under an Out-of-Africa demographic model. Each 
point represents a genetic architecture tested with 10 independent simulations under the RVAT 
indicated; lines connect the same simulated parameters across RVATs to show that, generally 
speaking, the rank of statistical power is preserved across RVATs. 
 
As rare variants explain more genetic variance of the trait, RVAT power decreases 
We then ask how RVAT power changes as a function of genetic architecture. In Figure 3.3, 
we show that as V0.01 increases (i.e., as rare variants explain increasing amounts of the genetic 
variance of the trait), the power of SKAT-O decreases. This pattern holds across all sampling 
strategies and for different levels of polygenicity (Figure S3). These results show patterns that will 
repeat in future sections: the extremes study design demonstrates the best overall power, followed 
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by 50/50 and then random. Further, a more concentrated signal (higher heritability and/or lower 
number of causal loci, see Supplemental Figures) improves power. We found that as the functional 
form relating effect size to selection coefficient changes from 𝜏𝜏=0.5 to 𝜏𝜏=1, power increases 
slightly again, suggesting that V’0.01 may be an overly simplistic characterization of the genetic 
architecture. Finally, applying SKAT-O to imputed data (bottom facet) reproduces all of the 
patterns we see when RVATs are applied to sequencing data (top facet), albeit with slightly worse 
power. Across tests, we see what Figures 3.3 and 3.4 indicated – that SKAT and KBAC perform 
worse than SKAT-O in general across all genetic architectures (see Figures B.1. through B.10.). 
We also note that RVATs are less effective in the European population, reflecting the increased 
number of rare variants as a result of explosive recent population growth in the Tennessen 
demographic model.  
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Figure 3.5 The statistical power of SKAT-O in African populations across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 100 causal loci of 10kb each across a 5Mb simulated 
region for a given genetic architecture for a 50,000 individual African population.  
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Using extreme cases/controls as sampling strategy improves statistical power of SKAT-O 
The number of individuals sequenced as part of a study is a key design parameter of that 
study. To understand how increasing the number of individuals improves the statistical power of 
SKAT-O, we simulate across genetic architectures and study designs to find the increase in power 
per individual using SKAT-O from 2,500 to 20,000 individuals (Figure 4). In the extremes study 
design, where half of the individuals in the panel are selected from the extreme cases and half of 
the individuals are selected from the extreme controls (from a total population of 50,000 
individuals), we find that mean power gain is zero. Increasing the number of individuals in this 
design means more individuals are drawn from closer to the mean of the distribution, so power is 
already maximized with a smaller sample of 2,500 individuals (and may actually decrease under 
some scenarios!). In the random and 50/50 study designs, increasing the size of the case/control 
panel increases the number of relevant individuals, and so mean power gain is approximately 2e-
5 per individual added. This increase is highly dependent on the genetic architecture underlying 
the trait of interest. These increases are consistent across populations and across RVATs studied, 
though the increase in power per individual added is lower using KBAC (see Figures C.1., C.2., 
and C.3.). 
42 
 
 
Figure 4.1 Increase in SKAT-O power as a function of sample size in an African population. 
SKAT-O power increases when increasing the sample size in non-extreme sampling strategies. 
Each point represents the slope from increasing the number of individuals in the case/control panel 
under a simulated genetic architecture. 
RVATs perform nearly as well on imputed data as they do on sequence data 
Most genetic association studies have started with genotyping arrays to collect genomic 
data, followed by imputation against WGS reference panels to maximize discovery potential 
with single variant analyses. As WGS cost falls, more studies will conduct large-scale WGS, but 
here we ask if there is a potential opportunity to discover rare variant associations with imputed 
data. In Figure 5, we compare the mean power of SKAT-O when applied to genotyped-then-
imputed samples to the mean power of SKAT-O applied to sequencing data from the same 
samples. We find that the decrease in power is minimal. Indeed, we find a robust linear 
relationship between RVAT power with sequencing vs imputed data, suggesting that for all 
scenarios evaluated here, imputation loses 10% power, on average, compared to sequencing data. 
This trend holds across European and African populations and across tests, except in the case of 
KBAC with European populations (Figure C.5.). This suggests that burden tests are less capable 
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of handling recent explosive population growth leading to an introduction of more ultra-rare 
variants within a population.  
 
Figure 4.2 The mean power of SKAT-O across different genetic architectures using imputed 
data, compared to using sequence data. Each point represents a different simulated genetic 
architecture where we vary the number of causal bins (10 or 100), heritability (0.2 or 0.8), sampling 
strategy, (⍴, 𝜏𝜏) for the underlying phenotype distribution, and the number of simulated case/control 
individuals in the study. The red line indicates the best linear fit with a slope is 0.92, interpreted 
as imputed data produces 92% of the power expected from WGS data. 
RVATs under a GWAS peak 
The general process of discovering genetic associations typically begins with genotyping 
and imputing a sample of individuals, followed by GWAS. The (typically unknown) genetic 
architecture of the trait determines the likelihood that a common variant will be detected with 
GWAS, and whether a rare variant association signal should be expected. Rastering over 
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parameters of our phenotype model, a genome-wide significant single marker association (GWAS) 
was identified at 44.4% of causal loci. Figure 4.3 shows the power of SKAT-O using sequencing 
or imputed data conditional on seeing (circles) or not seeing (x’s) a statistically significant GWAS 
hit at a causal locus. We find that under all phenotype model parameters and sampling strategies 
evaluated, when a GWAS hit is identified, SKAT-O has at least 70% power to detect a rare variant 
signal with sequence data (and slightly less power with imputed data), except when 𝑉𝑉0.01′  is almost 
1. If no GWAS peak is identified, there is considerably less power to identify a rare variant signal 
(and power further erodes as the genetic variance explained by rare variants increases). In a 
simulated European population, the power of RVATs is decreased due to increased numbers of 
rare variants and that patterns is observed whether GWAS detected a causal loci or not. Across 
tests, SKAT-O power is highest regardless of whether the causal loci was detected by GWAS or 
not. 
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Figure 4.3 The statistical power of GWAS given the results of SKAT-O in an African 
population, across different sequencing methods (rows) and across different sampling strategies 
(columns), as a function of the cumulative genetic variance explained by variants under 1% minor 
allele frequency. The shape shows the prediction of SKAT-O; the colours show the underlying 
number of causal loci and heritability of the trait.  
We then mimic the process of first doing locus discovery on a sample of imputed 
individuals followed by sequencing for different sampling strategies. In Figure 4.4, we show that 
sequencing data has at least 75% power to replicate causal loci identified with imputed data 
(regardless of the genetic architecture and case-control sampling strategy). However, when no 
association is found with imputed data, power to identify causal loci with sequencing data is highly 
dependent on the case-control sampling strategy, and the overall heritability and genetic 
architecture of the trait (with power generally decreasing as V’0.01 increases). In an European 
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population, the test power is lower across the board. Across tests, SKAT-O remains the highest 
powered test, although SKAT remains fairly close in performance.  
 
 
Figure 4.4 SKAT-O power using sequencing data, given the results of SKAT-O applied to 
imputed data in a simulated African population. The shape indicates whether SKAT-O applied 
to imputed data correctly identified the causal locus (circles) or missed it (x). The colours show 
the underlying causal number of loci and heritability of the trait.  
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Window of discovery around causal loci 
In Figure 4.5, we plot the probability of SKAT-O detecting an association signal as a 
function of the distance from a causal locus. To benchmark the width of this discovery window, 
we use the full-width half-maximum statistic, which is the distance at which the probability of a 
significant association crosses below 50% of its maximum value (i.e. falls below 50% of the 
power estimated at the causal locus). Consistent with previous results, the full-width half-
maximum is largest when there is a large amount of heritability concentrated in few causal loci 
and under the extremes study design. The larger points in Figure 8 represent this window of 
discovery, which is, on average, 34.3kb (sd 18.4kb) in the random study design, 42.8kb (sd 
19.3kb) in the 50/50 design, and 64.3kb (sd 34.2kb) in the extremes design. We observe similar 
trends within populations and across tests as observed before – the window of discovery is larger 
for the simulated African population than for the European population, and SKAT-O gives the 
largest window of discovery across tests, reflecting its ability to detect causal regions and 
neighboring loci. 
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Figure 4.5 The window of discovery around causal loci in an African population using SKAT-
O, shown as the fraction of simulations that result in a statistically significant RVAT p-value as a 
function of distance from the nearest causal locus. Different sampling strategies are shown in 
columns, and V0.01 thresholds  are shown in rows. Error bars are binomial standard errors of the 
mean. Bigger points represent full-width half-maximum points.  
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Genome-wide association studies (GWAS) so far have produced thousands of SNP 
associations for hundreds of traits (Buniello et al., 2019). However, in these GWAS, the associated 
SNPs do not recapitulate the estimated heritability of the trait, leading to the problem of “missing 
heritability”. Though there are many proposed sources of this missing heritability, one popular 
hypothesis is that this missing heritability resides in rare variants. This has led to the development 
of rare variant association tests and massive investment in large whole genome sequencing studies. 
With these tests and this data becoming more and more prevalent, we look at how to optimize the 
design of a rare variant association study to maximize power. 
It is clear that RVATs can be very powerful for detecting associations under simple genetic 
architectures [like when the effect size is proportional to log10(MAF) as proposed by (Wu et al., 
2011)]. Such phenotype models do not take into account evolutionary forces like natural selection 
and demography, and it is well appreciated that genetic architectures are sensitive to these non-
equilibrium evolutionary forces (Gazave, Chang, Clark, & Keinan, 2013; Simons, Turchin, 
Pritchard, & Sella, 2014). Uricchio et al presented a phenotype model that accounts for selection 
and pleiotropy and showed that existing RVATs struggle at realistic variance explained in genes 
across different human demographic histories (Uricchio et al., 2016). The Uricchio model captures 
modularity through the parameter ⍴ and the relationship between selection and effect size through 
𝜏𝜏, which enables a thorough exploration of different genetic architectures a trait could have (Figure 
1). 
We showed analytically that there is a significant amount of genetic variance explained in 
rare variants across different (⍴, 𝜏𝜏) parameterizations under the Uricchio model (Figure 1), 
particularly when 𝜏𝜏 is equal to 1. These results are not surprising, as it has been shown that a 
substantial amount of heritability derives from rare variants in real traits like gene expression 
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(Hernandez et al., 2017), height and BMI (Wainschtein et al., 2019). Taken together, the significant 
amount of heritability explained by rare variants under different parameterizations of the Uricchio 
model shows that RVATs have the potential to associate much of the causal variation underlying 
a complex trait. 
Many existing rare variant association tests were thoroughly characterized by (Moutsianas 
et al., 2015). We chose the most powerful representatives of the three classes of RVATs to use in 
our study: a variance-component test (SKAT), a burden method (KBAC), and a combined method 
(SKAT-O). Across all genetic architectures and study designs, we found that SKAT-O is the best 
performer, so we used SKAT-O in all further analyses on RVAT power in a case/control 
association study. 
To run a case/control association study, the first step is to determine which individuals to 
select for your study, and how to acquire their genetic data. We simulated three different sampling 
strategies: randomly sampling cases and controls proportional to the trait prevalence; sampling 
half of your study size from cases and half from your controls; and sampling individuals from the 
extreme tails of a quantitative distribution [or a proxy underlying the trait such as bronchodilator 
response (Spear et al., 2018), for example]. Our results show that choosing from the tails of an 
underlying quantitative distribution produces the best power. This means for any case/control 
association study, spending some time to find the extreme tails of an underlying quantitative 
distribution for a trait will likely produce the best possible RVAT power. 
We considered two ways of acquiring genetic data: using a genotyping array followed by 
imputation against a large reference panel, and direct sequencing of your study sample. Although 
a $1,000 whole genome is now possible, over the sample sizes required for an effective rare variant 
association study, the cost is prohibitive except for the largest consortia. Using genotyping arrays 
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then imputing is still much less expensive than WGS (Quick et al., 2019), which could enable more 
than 5x more genotyped samples than WGS samples. Practically speaking, this multiplier could 
be higher, as the cost to enroll a new individual and acquire their WGS and phenotype data is much 
higher than genotyping.  
Applying SKAT-O to imputed data is expected to have lower power for several reasons. 
First, imputation accuracy decreases as MAF decreases (Howie, Marchini, Stephens, & 
Chakravarti, 2011; Quick et al., 2019), meaning fewer rare variants will be accurately imputed and 
correctly identified in the study sample. Second, imputation accuracy is highest when the study 
sample population and the reference panel population match, and this is not guaranteed to be the 
case, particularly when the study sample is from a minority population or an admixed population. 
Third, a majority of rare variants carried by the imputed samples are unlikely to be carried by the 
reference panel.  
Comparing SKAT-O power across genetic architectures and study designs, we show that 
genotyping then imputing is about 90% as powerful as WGS using the same number of individuals. 
We note here again that genotyping error is not simulated, and so this result is an upper bound on 
SKAT-O power using imputed data. This implies that using genotyping then imputing with a larger 
sample size could produce as much if not more power than a smaller WGS sample. For most 
current rare variant association studies, our results suggest that using genotyping then imputing is 
the most cost-effective way to proceed. We also looked at the increase in SKAT-O power using 
WGS after running a genotyping and imputation study; there is a boost in SKAT-O power when 
using WGS data following imputed data, but the trade-off between cost and power is something 
to be considered on an individual study basis. 
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The next step in characterizing RVAT power is to consider the genetic architecture of the 
trait of interest. Though complex trait architectures are not thoroughly understood, we used the 
Uricchio model to simulate different architectures and label these architectures using the amount 
of cumulative genetic variance explained by all variants under 1% minor allele frequency (V’0.01). 
We show that SKAT-O power decreases as V0.01 increases, meaning SKAT-O performance is 
worst when rare alleles make the largest contributions to trait variance. Although counterintuitive, 
as one would expect RVATs are best tuned for the scenarios where rare variants matter most in 
the genetic architecture, our result mirrors the findings of Uricchio et al, 2016. One explanation is 
that as V0.01 goes up, the proportion of V0.01 due to singletons and other ultra-rare alleles increases 
as well, and statistically associating these ultra-rare alleles is difficult in the RVAT frameworks 
we evaluated here. We also note that the explosive exponential growth of the Tennessen 
demographic model used to simulate genetic data leads to an excess of ultra-rare alleles compared 
to the neutral expectation, such that both cases and controls harbor many ultra-rare variants 
(thereby confounding RVAT power). The converse may be true in a population that has not 
experienced recent explosive population growth – with fewer relative ultra-rare alleles, RVAT 
power may increase in these populations. 
With the decrease in power as rare variants mattered more, we wondered whether nearby 
regions in rare variant-dominated architectures would provide additional information. We looked 
at how the probability of SKAT-O detecting a causal region decreases as a function of distance 
from a causal region. The results suggest that in an unbiased window-based approach to scanning 
the genome with SKAT-O, positive hits that are not in causal regions may be useful in helping 
identify true causal regions, although again only in genetic architectures where rare variants do not 
contribute the majority of genetic variance. Interestingly, the power ranking of study designs is 
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inverse of the ranking of precision, meaning that with higher power comes a larger window of 
discovery. 
We also looked at the statistical properties of a common analytical path from GWAS to 
RVATs, and from imputed data to sequence data. We found that GWAS and SKAT-O are 
generally concordant, with causal regions identified by GWAS being identified by SKAT-O, while 
a smaller proportion (~15%) of causal regions are identified by SKAT-O and not by GWAS. We 
see little downside in testing for causal regions using SKAT-O following GWAS, with the ability 
to pick up additional causal regions on the same data. We caution that this effect declines 
significantly as rare variants explain more of the genetic variance.  
Finally, the number of loci contributing to a trait (or its polygenicity) may be another 
important component of the trait’s architecture. It is not surprising that we found that for a fixed 
heritability of a trait, RVAT discovery power is higher when there are fewer true causal loci (as 
effect sizes are concentrated into fewer variants). However, it is possible that the polygenicity of 
a trait could be constraining the possible range of genetic architectures. 
We observed the same patterns for all parameters across populations and across tests. In 
general, the European population experienced a recent explosive population growth, leading to the 
introduction of larger numbers of ultra-rare variants (singletons, mostly) compared to the African 
population. This introduction of ultra-rare variants reduces the power of every statistical test used, 
particularly the burden test KBAC. Given that KBAC is the worst performing test across the 
genetic architectures and study designs, we suggest using SKAT-O as the default standard RVAT 
for future studies 
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This study has a few limitations. It is based on simulated data that matches inferred human 
evolutionary history (including selection, and demographic history) but these models and 
simulations are incomplete representations of nature. We do not explore the effects of gene size, 
mutation rate, haplotype length, or degree of linkage disequilibrium between causal regions. We 
do not consider the differences between coding and non-coding regions, which have different 
selection coefficient distributions and potentially different contributions to the genetic 
architectures for a trait. Future work should consider a phenotype model where the function of a 
region is taken into account, as ENCODE (The ENCODE Project Consortium, 2012) and other 
consortia are rapidly adding more dimensions to genomic data. One major shortcoming is that we 
analyze only African and European populations in this study. With significant growth in admixed 
populations already happening - the US Census in 2014-15 predicts that the US will be a “majority-
minority” country by 2050 (Projections of the Size and Composition of the U.S. Population: 2014 
to 2060, 2014), meaning significant growth in African-American and Latino populations - it will 
be important to study association testing power in admixed populations. We also believe that 
incorporating functional annotations, evolutionary forces, and admixture into rare variant 
association tests would significantly improve statistical power. 
This study shows that RVATs have little power in regimes where rare variants truly matter. 
We suggest three future directions to investigate the role of rare variants within genetic 
architectures and improve upon RVAT power. First, Haseman-Elston regression on simulated 
genetic architectures revealed that simulating a 5Mb locus generates too few rare variants to get a 
significant effect. At maximum, we simulate causal regions totaling 1Mb, which is insufficient to 
have ultra-rare variants make a large impact on heritability. Under some simulated genetic 
architectures, these ultra-rare variants are expected to contribute the majority of heritability. This 
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is reflected in real complex traits, where rare variants contribute a majority of heritability in gene 
expression (Ryan D. Hernandez et al., 2017). One future direction is therefore to discover the 
causal region size necessary for ultra-rare variants to make a significant contribution to heritability 
under different genetic architectures, which can help guide design of genetic association studies 
when the size of causal region is better understood. 
Another obvious avenue is to incorporate functional annotations in improving the power 
of genetic association studies. With the ENCODE project (The ENCODE Project Consortium, 
2012) annotating much of the genome, we now have the functional annotations to pair with genetic 
data gathered in any study. Though this has been pursued in various guises to date (Hormozdiari 
et al., 2018; Kichaev et al., 2014; Pickrell, 2014), the results have been lackluster and further 
improvements in both data and method will improve RVAT power. 
Last, we propose simulating theoretical models that explain patterns of heritability within 
complex traits like the omnigenic model (Boyle, Li, & Pritchard, 2017) and various polygenic 
models [like (Uricchio et al., 2016) and others] to investigate the properties of RVATs under these 
theoretical models and suggest mechanisms for improving current statistical methods. This work 
would also serve as a reference for future genetic association studies as a comparison for their 
empirical results to determine the closest model underlying the complex trait under study.  
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Appendix A: Supplemental Material to Chapter 3 
 
Figure A.1 The statistical power of SKAT-O in European populations across different 
sampling strategies (columns) and across different sequencing methods (rows), as a function of 
the proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 100 causal loci of 10kb each across a 5Mb simulated 
region for a given genetic architecture for a 50,000 individual African population.  
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Figure A.2 The statistical power of KBAC in African populations across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 100 causal loci of 10kb each across a 5Mb simulated 
region for a given genetic architecture for a 50,000 individual African population.  
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Figure A.3 The statistical power of KBAC in European populations across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 100 causal loci of 10kb each across a 5Mb simulated 
region for a given genetic architecture for a 50,000 individual African population.  
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Figure A.4 The statistical power of SKAT in African populations  across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 100 causal loci of 10kb each across a 5Mb simulated 
region for a given genetic architecture for a 50,000 individual African population.  
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Figure A.5 The statistical power of SKAT in European populations across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 100 causal loci of 10kb each across a 5Mb simulated 
region for a given genetic architecture for a 50,000 individual European population.  
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Figure A.6 The statistical power of SKAT-O in African populations  across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 10 or 100 causal loci of 10kb each across a 5Mb 
simulated region for a given genetic architecture for a 50,000 individual African population.  
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Figure A.7 The statistical power of SKAT-O in European populations  across different 
sampling strategies (columns) and across different sequencing methods (rows), as a function of 
the proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 10 or 100 causal loci of 10kb each across a 5Mb 
simulated region for a given genetic architecture for a 50,000 individual European population.  
 
72 
 
  
Figure A.8 The statistical power of KBAC in African populations across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 10 or 100 causal loci of 10kb each across a 5Mb 
simulated region for a given genetic architecture for a 50,000 individual African population.  
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Figure A.9 The statistical power of KBAC in European populations across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 10 or 100 causal loci of 10kb each across a 5Mb 
simulated region for a given genetic architecture for a 50,000 individual European population.  
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Figure A.10 The statistical power of SKAT in African populations across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 10 or 100 causal loci of 10kb each across a 5Mb 
simulated region for a given genetic architecture for a 50,000 individual African population.  
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Figure A.11 The statistical power of SKAT in European populations  across different sampling 
strategies (columns) and across different sequencing methods (rows), as a function of the 
proportion of genetic variance explained by that genetic architecture at MAF=1%. Each point 
represents 20 independent simulations of 10 or 100 causal loci of 10kb each across a 5Mb 
simulated region for a given genetic architecture for a 50,000 individual European population.  
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Appendix B: Supplemental Material to Chapter 4 
 
Figure B.1 Increase in SKAT-O power as a function of sample size in an European 
population. SKAT-O power increases when increasing the sample size in non-extreme sampling 
strategies. Each point represents the slope from increasing the number of individuals in the 
case/control panel under a simulated genetic architecture. 
 
 
Figure B.2 Increase in KBAC power as a function of sample size in an African (left) and 
European (right) population. KBAC power increases when increasing the sample size in non-
extreme sampling strategies. Each point represents the slope from increasing the number of 
individuals in the case/control panel under a simulated genetic architecture. 
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Figure B.3 Increase in SKAT power as a function of sample size in an African (left) and 
European (right) population. SKAT power increases when increasing the sample size in non-
extreme sampling strategies. Each point represents the slope from increasing the number of 
individuals in the case/control panel under a simulated genetic architecture. 
 
 
Figure B.4 The mean power of SKAT-O in an European population across different genetic 
architectures using imputed data, compared to using sequence data. Each point represents a 
different simulated genetic architecture where we vary the number of causal bins (10 or 100), 
heritability (0.2 or 0.8), sampling strategy, (⍴, 𝜏𝜏) for the underlying phenotype distribution, and 
the number of simulated case/control individuals in the study. The red best fit line has slope 0.89. 
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Figure B.5  The mean power of KBAC in an African (left) and European (right) population 
across different genetic architectures using imputed data, compared to using sequence data.  
Each point represents a different simulated genetic architecture where we vary the number of 
causal bins (10 or 100), heritability (0.2 or 0.8), sampling strategy, (⍴, 𝜏𝜏) for the underlying 
phenotype distribution, and the number of simulated case/control individuals in the study. The best 
fit line in red has a slope of 0.89 in Africans and 0.79 in Europeans.  
.   
Figure B.6 The mean power of SKAT in an African (left) and European (right) population 
across different genetic architectures using imputed data, compared to using sequence data. 
Each point represents a different simulated genetic architecture where we vary the number of 
causal bins (10 or 100), heritability (0.2 or 0.8), sampling strategy, (⍴, 𝜏𝜏) for the underlying 
phenotype distribution, and the number of simulated case/control individuals in the study. The best 
fit line in red has a slope of 0.92 in Africans and 0.89 in Europeans.  
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Figure B.7 The statistical power of GWAS given the results of SKAT-O in an European 
population , across different sequencing methods (rows) and across different sampling strategies 
(columns), as a function of the cumulative genetic variance explained by variants under 1% minor 
allele frequency. The shape shows the prediction of SKAT-O; the colours show the underlying 
number of causal loci and heritability of the trait.  
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Figure B.8 The statistical power of GWAS given the results of KBAC in an African 
population , across different sequencing methods (rows) and across different sampling strategies 
(columns), as a function of the cumulative genetic variance explained by variants under 1% minor 
allele frequency. The shape shows the prediction of KBAC; the colours show the underlying 
number of causal loci and heritability of the trait.  
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Figure B.9 The statistical power of GWAS given the results of KBAC in an European 
population, across different sequencing methods (rows) and across different sampling strategies 
(columns), as a function of the cumulative genetic variance explained by variants under 1% minor 
allele frequency. The shape shows the prediction of KBAC; the colours show the underlying 
number of causal loci and heritability of the trait.  
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Figure B.10 The statistical power of GWAS given the results of SKAT in an African 
population , across different sequencing methods (rows) and across different sampling strategies 
(columns), as a function of the cumulative genetic variance explained by variants under 1% minor 
allele frequency. The shape shows the prediction of SKAT; the colours show the underlying 
number of causal loci and heritability of the trait.  
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Figure B.11 The statistical power of GWAS given the results of SKAT in an European 
population, across different sequencing methods (rows) and across different sampling strategies 
(columns), as a function of the cumulative genetic variance explained by variants under 1% minor 
allele frequency. The shape shows the prediction of SKAT; the colours show the underlying 
number of causal loci and heritability of the trait.  
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Figure B.12 SKAT-O power using sequencing data, given the results of SKAT-O applied to 
imputed data in an European population. The shape indicates whether SKAT-O applied to 
imputed data correctly identified the causal locus (circles) or missed it (x). The colours show the 
underlying causal number of loci and heritability of the trait.  
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Figure B.13 KBAC power using sequencing data, given the results of KBAC applied to 
imputed data in an African population.  The shape indicates whether KBAC applied to imputed 
data correctly identified the causal locus (circles) or missed it (x). The colours show the underlying 
causal number of loci and heritability of the trait.  
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Figure B.14 KBAC power using sequencing data, given the results of KBAC applied to 
imputed data in an European population.  The shape indicates whether KBAC applied to 
imputed data correctly identified the causal locus (circles) or missed it (x). The colours show the 
underlying causal number of loci and heritability of the trait.  
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Figure B.15 SKAT power using sequencing data, given the results of SKAT applied to 
imputed data in an African population. The shape indicates whether SKAT applied to imputed 
data correctly identified the causal locus (circles) or missed it (x). The colours show the underlying 
causal number of loci and heritability of the trait.  
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Figure B.16 SKAT power using sequencing data, given the results of SKAT applied to 
imputed data in an European population. The shape indicates whether SKAT applied to 
imputed data correctly identified the causal locus (circles) or missed it (x). The colours show the 
underlying causal number of loci and heritability of the trait.  
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Figure B.17 The window of discovery around causal loci in an European population using 
SKAT-O, shown as the fraction of simulations that result in a statistically significant RVAT p-
value as a function of distance from the nearest causal locus. Different sampling strategies are 
shown in columns, and V0.01 thresholds are shown in rows. Error bars are binomial standard errors 
of the mean. Bigger points represent full-width half-maximum points.  
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Figure B.18 The window of discovery around causal loci in an African population using 
KBAC, shown as the fraction of simulations that result in a statistically significant RVAT p-value 
as a function of distance from the nearest causal locus. Different sampling strategies are shown in 
columns, and V0.01 thresholds are shown in rows. Error bars are binomial standard errors of the 
mean. Bigger points represent full-width half-maximum points.  
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Figure B.19 The window of discovery around causal loci in an European population using 
KBAC, shown as the fraction of simulations that result in a statistically significant RVAT p-value 
as a function of distance from the nearest causal locus. Different sampling strategies are shown in 
columns, and V0.01 thresholds are shown in rows. Error bars are binomial standard errors of the 
mean. Bigger points represent full-width half-maximum points.  
92 
 
  
Figure B.20 The window of discovery around causal loci in an African population using 
SKAT, shown as the fraction of simulations that result in a statistically significant RVAT p-value 
as a function of distance from the nearest causal locus. Different sampling strategies are shown in 
columns, and V0.01 thresholds are shown in rows. Error bars are binomial standard errors of the 
mean. Bigger points represent full-width half-maximum points.  
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Figure B.21 The window of discovery around causal loci in an European population using 
SKAT , shown as the fraction of simulations that result in a statistically significant RVAT p-value 
as a function of distance from the nearest causal locus. Different sampling strategies are shown in 
columns, and V0.01 thresholds are shown in rows. Error bars are binomial standard errors of the 
mean. Bigger points represent full-width half-maximum points. 
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